Page last updated: 2024-09-04

moxifloxacin and framycetin

moxifloxacin has been researched along with framycetin in 3 studies

Compound Research Comparison

Studies
(moxifloxacin)
Trials
(moxifloxacin)
Recent Studies (post-2010)
(moxifloxacin)
Studies
(framycetin)
Trials
(framycetin)
Recent Studies (post-2010) (framycetin)
3,1575521,6908,151460653

Protein Interaction Comparison

ProteinTaxonomymoxifloxacin (IC50)framycetin (IC50)
30S ribosomal protein S6Escherichia coli K-120.032
30S ribosomal protein S7Escherichia coli K-120.032
50S ribosomal protein L15Escherichia coli K-120.032
50S ribosomal protein L10Escherichia coli K-120.032
50S ribosomal protein L11Escherichia coli K-120.032
50S ribosomal protein L7/L12Escherichia coli K-120.032
50S ribosomal protein L19Escherichia coli K-120.032
50S ribosomal protein L1Escherichia coli K-120.032
50S ribosomal protein L20Escherichia coli K-120.032
50S ribosomal protein L27Escherichia coli K-120.032
50S ribosomal protein L28Escherichia coli K-120.032
50S ribosomal protein L29Escherichia coli K-120.032
50S ribosomal protein L31Escherichia coli K-120.032
50S ribosomal protein L31 type BEscherichia coli K-120.032
50S ribosomal protein L32Escherichia coli K-120.032
50S ribosomal protein L33Escherichia coli K-120.032
50S ribosomal protein L34Escherichia coli K-120.032
50S ribosomal protein L35Escherichia coli K-120.032
50S ribosomal protein L36Escherichia coli K-120.032
30S ribosomal protein S10Escherichia coli K-120.032
30S ribosomal protein S11Escherichia coli K-120.032
30S ribosomal protein S12Escherichia coli K-120.032
30S ribosomal protein S13Escherichia coli K-120.032
30S ribosomal protein S16Escherichia coli K-120.032
30S ribosomal protein S18Escherichia coli K-120.032
30S ribosomal protein S19Escherichia coli K-120.032
30S ribosomal protein S20Escherichia coli K-120.032
30S ribosomal protein S2Escherichia coli K-120.032
30S ribosomal protein S3Escherichia coli K-120.032
30S ribosomal protein S4Escherichia coli K-120.032
30S ribosomal protein S5Escherichia coli K-120.032
30S ribosomal protein S8Escherichia coli K-120.032
30S ribosomal protein S9Escherichia coli K-120.032
50S ribosomal protein L13Escherichia coli K-120.032
50S ribosomal protein L14Escherichia coli K-120.032
50S ribosomal protein L16Escherichia coli K-120.032
50S ribosomal protein L23Escherichia coli K-120.032
30S ribosomal protein S15Escherichia coli K-120.032
50S ribosomal protein L17Escherichia coli K-120.032
50S ribosomal protein L21Escherichia coli K-120.032
50S ribosomal protein L30Escherichia coli K-120.032
50S ribosomal protein L6Escherichia coli K-120.032
30S ribosomal protein S14Escherichia coli K-120.032
30S ribosomal protein S17Escherichia coli K-120.032
30S ribosomal protein S1Escherichia coli K-120.032
50S ribosomal protein L18Escherichia coli K-120.032
50S ribosomal protein L2Escherichia coli K-120.032
50S ribosomal protein L3Escherichia coli K-120.032
50S ribosomal protein L24Escherichia coli K-120.032
50S ribosomal protein L4Escherichia coli K-120.032
50S ribosomal protein L22Escherichia coli K-120.032
50S ribosomal protein L5Escherichia coli K-120.032
30S ribosomal protein S21Escherichia coli K-120.032
50S ribosomal protein L25Escherichia coli K-120.032
50S ribosomal protein L36 2Escherichia coli K-120.032

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's1 (33.33)24.3611
2020's2 (66.67)2.80

Authors

AuthorsStudies
Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A1
Xu, Z1
Bhamare, P; Dunman, PM; Johnson, W; Kinn, B; Laskey, E; Mei, JA; Nolin, L; Stalker, C; Wozniak, RAF1

Reviews

1 review(s) available for moxifloxacin and framycetin

ArticleYear
1,2,3-Triazole-containing hybrids with potential antibacterial activity against methicillin-resistant Staphylococcus aureus (MRSA).
    European journal of medicinal chemistry, 2020, Nov-15, Volume: 206

    Topics: Anti-Bacterial Agents; Drug Design; Methicillin-Resistant Staphylococcus aureus; Triazoles

2020

Other Studies

2 other study(ies) available for moxifloxacin and framycetin

ArticleYear
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
    Chemical research in toxicology, 2010, Volume: 23, Issue:1

    Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship

2010
Antimicrobial Activity of a Triple Antibiotic Combination Toward Ocular Pseudomonas aeruginosa Clinical Isolates.
    Translational vision science & technology, 2022, 05-02, Volume: 11, Issue:5

    Topics: Anti-Bacterial Agents; Bacitracin; Drug Combinations; Erythromycin; Framycetin; Humans; Keratitis; Levofloxacin; Moxifloxacin; Polymyxin B; Pseudomonas aeruginosa; Pseudomonas Infections; Rifampin; Tobramycin; Trimethoprim

2022